Suneil Hosmane
Vice President, Diagnostic Strategy Madrigal Pharmaceuticals
Seminars
Tuesday 15th September 2026
Advancing Imaging & Non-Invasive Biomarker Strategies to Improve Endpoint Interpretation, Enable Earlier Decision-Making & Support Registrational Success in Mash
10:00 am
- Evaluating complementary imaging and biomarker approaches to generate a more comprehensive understanding of disease progression and treatment response, enabling more informed development decisions and strengthening clinical confidence
- Correlating non-invasive biomarker changes with clinically meaningful fibrosis outcomes to improve endpoint relevance, supporting broader adoption across MASH development programs
- Integrating scalable monitoring approaches into late-stage clinical strategies to improve operational efficiency, strengthening long-term applicability and future treatment implementation
